SDP Oncology Announces New Data from Phase 1 Solid Tumor Study
September 25, 2020
Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) and BioUtah member recently announced new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903) in patients with advanced solid tumors.
“These preliminary data presented at ESMO 2020 are encouraging as we learn more about how dubermatinib may inhibit the AXL kinase protein and sensitize cancer cells to treatment with other targeted agents in patients with advanced solid tumors,” said David J. Bearss, Ph.D., Chief Scientific Officer and Global Head of Research, SDP Oncology.
“This is an impressive development,” said Kelvyn Cullimore, president and CEO of BioUtah. “SDP Oncology is offering new hope for many cancer patients. We look forward to following the study as it advances.”
These results were presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress held September 19-21. Preliminary findings showed that dubermatinib, as a single agent and as part of the combination regimens, was well-tolerated with a manageable safety profile.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
